[1] Smith GP. Filamentous fusion phage:novel expression vectors that display cloned antigens on the virion surface[J]. Science, 1985, 228(4705):1315-1317.
[2] Kehoe JW, Kay BK. Filamentous phage display in the new millennium[J]. Chem Rev, 2005, 105(11):4056-4072.
[3] Lanner RC, Sato AK, Gorzelany J, et al. Phage display-derived peptides as therapeutic alternatives to antibodies[J]. Drug Discov Today, 2004, 9(12):525-529.
[4] Ruoslahti E. Drug targeting to specific vascular sites[J]. Drug Discov Today, 2002, 7(22):1138-1143.
[5] Hajitou A, Pasquallni R, Arap W. Vascular targeting:recent advances and therapeutic perspectives[J]. Trends Cardiovasc Med, 2006, 16(3):80-88.
[6] Zurita AJ, Arap W, Pasqualini R. Maping tumor vascular diversity by screening phage display libraries[J]. J Control Release, 2003, 91(1-2):183-186.
[7] Neri D, Bicknell R. Tumour vascular targeting[J]. Nat Rev Cancer, 2005, 5(6):436-446.
[8] George AJ, Lee L, Pitzalis C. Isolating ligands specific for human vasculature using in vivo phage selection[J]. Trends Biotechnol, 2003, 21(5):199-203.
[9] Landon LA, Deutscher SL. Combinatorial discovery of tumor targeting peptides using phage display[J]. J Cell Biochem, 2003, 90(3):509-517.
[10] Liu C, Bhattacharjee G, Boisvert W, et al. In vivo interrogation of the molecular display of atherosclerotic lesion surfaces[J]. Am J Pathol, 2003, 163(5):1859-1871.
[11] Kelly KA, Nahrendorf M, Yu AM, et al. In vivo phage display selection yields atherosclerotic plaque targeted peptides for imaging[J]. Mol Imaging Biol, 2006, 8(4):201-207.
[12] Landon LA, Zou J, Deutscher SL. Is phage display technology on target for developing peptide-based cancer drugs?[J]. Curr Drug Discov Technol, 2004, 1(2):113-132.
[13] Trepel M, Arap W, Pasqualini R. In vivo phage display and vascular heterogeneity:implications for targeted medicine[J]. Curr Opin Chem Biol, 2002, 6(3):399-404.
[14] Kolonin MG, Saha PK, Chan L, et al. Reversal of obesity by targeted ablation of adipose tissue[J]. Nat Med, 2004, 10(6):625-632.
[15] Arap W, Kolonin MG, Trepel M, et al. Steps toward mapping the human vasculature by phage display[J]. Nat Med, 2002, 8(2):121-127.
[16] Ruoslahti E. Vascular zip codes in angiogenesis and metastasis[J]. Biochem Soc Trans, 2004, 32(pt3):397-402.
[17] Zurita A, Troncoso P, Cardo-Vila M, et al. Combinatorial screenings in patients:the interleukin-11 receptor as a candidate target in the progression of human prostate cancer[J]. Cancer Res, 2004, 64(2):435-439.
[18] Essler M, Ruoslahti E. Molecular specialization of breast vaseulature:A breast-homing phage-displayed peptlde binds to aminopeptidase P in breast vasculature[J]. Proc Natl Acad Sci USA, 2002, 99(4):2252-2257.
[19] Laakkonen P, Porkka K, Hoffman JA, et al. A tumor-homing peptide with a targeting specificity related to lymphatic vessels[J]. Nat Med, 2002, 8(7):751-755.
[20] Laakkonen P, Akerman ME, Biliran H, et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells[J]. Proc Natl Acad Sci USA, 2004, 101(25):9381-9386.
[21] Krag DN, Shukla GS, Shen GP, et al. Selection of tumor-binding ligands in cancer patients with phage display libraries[J]. Cancer Res, 2006, 66(15):7724-7733.
[22] Sokolov K, Aaron J, Hsu B, et al. Optical systems for in vivo molecular imaging of cancer[J]. Technol Cancer Res Treat, 2003, 2(6):491-504.
[23] Denardo SJ. Combined molecular targeting for cancer therapy:a new paradigm in need of molecular imaging[J]. J Nucl Med, 2006, 47(1):4-5.
[24] Lewis MR. Radiolabeled RGD peptides move beyond cancer:PET imaging of delayed-type hypersensitivity reaction[J]. J Nucl Med, 2005, 46(1):2-4.